Electrophysiologic investigation in Brugada syndrome

Size: px
Start display at page:

Download "Electrophysiologic investigation in Brugada syndrome"

Transcription

1 European Heart Journal (2002) 23, doi: /euhj , available online at on Electrophysiologic investigation in Brugada syndrome Yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats L. Eckardt 1, P. Kirchhof 1, E. Schulze-Bahr 1, S. Rolf 1, M. Ribbing 1,P.Loh 1, H.-J. Bruns 1, A. Witte 1, P. Milberg 1, M. Borggrefe 2, G. Breithardt 1, T. Wichter 1 and W. Haverkamp 1 1 Hospital of the Westfälische Wilhelms-University, Department of Cardiology and Angiology and Institute for Arteriosclerosis Research, Münster, Germany; 2 University Hospital Mannheim, Mannheim, Germany Introduction Numerous reports on the inducibility of ventricular tachyarrhythmias (VT) in patients with atypical right bundle branch block and right precordial ST-elevation (Brugada syndrome) are based on multicentre studies that have used different stimulation protocols. Therefore, we prospectively investigated the inducibility of VT in these patients using a uniform protocol. Methods In 41 consecutive patients (29 males) showing a pattern of right bundle branch block and ST-elevation, programmed ventricular stimulation was performed in the right ventricular apex with up to three premature stimuli at sinus rhythm and at four different paced cycle lengths (500, 430, 370, and 330 ms) until refractoriness was reached or reproducible induction of a sustained (>30 s) VT occurred. If a VT was not reproducibly inducible, the same protocol was repeated in the right ventricular outflow tract. Results A history of life-threatening events defined as syncope (n=17) or aborted sudden cardiac death (n=13) was present in 30 patients (73%); 11 individuals were asymptomatic. Inducibility (68%) was similar between symptomatic (n=21, 70%) and asymptomatic patients (n=7, 64%). In 16 (39%) patients, VT were reproducibly inducible. If patients were only stimulated in the right ventricular apex, inducibility rate decreased to 39%. If only two premature beats at two sites were used it was as low as 32%. The mean coupling intervals of the second and third premature stimuli inducing sustained VT were short: ms vs ms, respectively. Forty-four percent of all patients (i.e. 64% of the inducible patients) had inducible VT only with coupling intervals shorter than 200 ms. Conclusions The stimulation protocol markedly influences the extent of inducibility of VT in patients with right bundle branch block and ST-segment elevation. These findings question the significance of previous multicentre studies using different stimulation protocols and should have implications for further studies. (Eur Heart J, 2002; 23: , doi: /euhj ) 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved. Key Words: Brugada syndrome, programmed ventricular stimulation Revision submitted 4 March 2002, and accepted 13 March Partly supported by: (1) Deutsche Forschungsgemeinschaft, Bonn, Germany (Schu 1082/2-2, later Sonderforschungsbereich 556; projects A1, C4), and (2)Alfried-Krupp-von-Bohlen-Halbach Foundation, Essen, Germany. (3) Grants from Interdisciplinary Center for Clinical Research Münster, Germany (BMBF, AZ 01 KS 9604) Correspondence: Dr med. Lars Eckardt, Medizinische Klinik und Poliklinik C, Kardiologie Angiologie, Universitätsklinikum Münster, Germany X/02/$ The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

2 Programmed electrical stimulation in Brugada syndrome 1395 Introduction In 1992, Brugada and Brugada [1] identified a syndrome characterized by atypical right bundle branch block and right precordial ST-elevation associated with episodes of syncope or sudden cardiac death caused by rapid polymorphic ventricular tachyarrhythmias (VT). This has now become known as a new entity called Brugada syndrome. It is a genetically transmitted disease that may cause sudden cardiac death in individuals without structural heart disease. Available multicentre data by Brugada et al. [2,3] have confirmed the malignant character of this syndrome showing that it is associated with a recurrence rate of arrhythmic events of about 40% in 3 years after the initial event of resuscitation or syncope and a 5% event rate in asymptomatic individuals. Programmed ventricular stimulation has been suggested as a means to identify patients at risk [4]. Brugada et al. [2] reported that the inducibility of VT was a good predictor of poor outcome in asymptomatic patients with an abnormal ECG. However, the results of programmed ventricular stimulation especially in asymptomatic individuals with the characteristic ECG findings have been controversial. In contrast to Brugada and coworkers, Priori et al. [5] published multicentre data that questioned the diagnostic predictive accuracy of programmed ventricular stimulation and the risk of cardiac events in asymptomatic patients. Thus, although programmed ventricular stimulation is largely used to define risk in Brugada syndrome caution about its prognostic value may be justified. As both reports were based on multicentre data, criticism has been raised that the differences in the data may in part be related to different stimulation protocols. The coupling intervals, the number of premature beats, and the stimulation sites have also not been systematically differentiated. Therefore, we prospectively investigated the yield of programmed ventricular stimulation using a uniform stimulation protocol with stimulation at two ventricular sites and at five different cycle lengths of basic drive with up to three premature stimuli in a large group of patients with an ECG pattern compatible with the Brugada syndrome. Patients and methods A total of 41 consecutive patients (29 males, 71%) were diagnosed to have an ECG compatible with the Brugada syndrome within the last 6 years in our institution (Münster, Germany). Structural heart disease was excluded after extensive evaluation, including echocardiography (n=41), coronary angiography (n=34), right (n=30) and left ventricular angiography (n=34), right ventricular biopsies (n=25), and nuclear MRI (n=19). Patients were divided into two groups depending on their clinical presentation at the time of diagnosis. The first group (Table 1) consisted of 30 symptomatic patients. Thirteen patients (12 male) had a history of documented ventricular fibrillation (VF) and aborted sudden cardiac death and 17 patients (nine male) had one or more unexplained episodes of syncope (group I). In addition, there were 11 (eight male) individuals with the characteristic ECG pattern but without a history of resuscitation or syncope (group II, Table 2). They were seen because of the characteristic ECG pattern diagnosed by their general practitioner (n=3; patients 31, 37, 40), a positive family history (n=8; patients 32, 34 38, 40, 41) and/or palpitations (n=2; patients 37, 38). The age of all patients at diagnosis ranged between 24 and 66 years (median years). The medical histories of all patients had been unremarkable before their first clinical presentation. Six patients (patients 24, 25, 36 39) had palpitations. In four patients (patients 24, 25, 37, 38), a regular supraventricular tachyarrhythmia had been documented [6]. All patients were unrelated except patients 14 and 25 (father/daughter), patients 5 and 36 (brother/sister), and patients 20 and 37 (sisters). Patients 36 and 37 presented to our department because of palpitations and relatives with known Brugada syndrome (patients 20 and 5, respectively). In 18 (44%) patients (patients 8, 13 16, 23 26, 29, 32, 34 38, 40, 41), there was a family history of sudden cardiac death and/or syncope. All except five patients (patients 2, 3, 13, 18, 19) were investigated for mutations in the sodium channel gene SCN5A. Three patients (8%, two were related) with a SCN5A mutation were identified. Patient 25 had a heterogeneous two-basepair deletion in SCN5A. This mutation was also found in her father (patient 14) but not in any other family member nor in a control sample of 100 unrelated, healthy individuals. Noteworthy, the father of patient 25 (patient 14) had no inducible VT despite having the same genotype as his daughter in whom VT was inducible. Electrocardiographic findings and electrophysiologic testing All patients had ECG documentation with RBBB and ST-segment elevation ( 0 2 mv) in the right precordial leads. The ECG was spontaneously abnormal in 28 patients and became abnormal after intravenous administration of ajmaline (1 mg. kg 1 body weight, 10 mg-. min 1 ) in the remaining 13 individuals. Ten (24%) patients (eight symptomatic patients) had a HV-interval 60 ms (Tables 1 and 2). Electrophysiologic testing was performed in the fasting, drug free, non-sedated state, after written informed consent had been obtained. At first, stimulation was performed in the right ventricular apex with one and two premature stimuli at sinus rhythm and at four different cycle lengths (500, 430, 370, and 330 ms). Premature beats were started in late diastole; coupling intervals were then reduced in decrements of 10 ms until refractoriness was reached. The endpoint of programmed ventricular stimulation was the

3 1396 L. Eckardt et al. Table 1 Clinical and electrophysiologic characteristics of Brugada patients presenting with cardiac arrest or syncope Pt. no. Sex/Age (years) Clinic Family history SCN5A Doc.arrhy. HV (ms) Induction Mode of VT/VF induction (ms) Therapy/Follow up 1 m/59 cardiac arrest 0 0 VF 50 VF RVA (500/230/170/230) RVA (500/230/180/180) ICD/64 2 m/36 cardiac arrest 0 VF 55 VF RVO (500/220/190) 0 ICD/53 3 m/30 cardiac arrest 0 VF 50 VF RVO (500/210/160/160) RVO (500/220/200/200) ICD/49 4 m/31 cardiac arrest 0 0 VF 40 VF RVA (430/220/240) RVA (500/230/170/220) ICD/75 5 m/37 cardiac arrest 0 0 VF 35 VF RVA (500/240/190/170) RVO (500/210/160) ICD/25 6 m/49 cardiac arrest 0 0 VF 60 VF RVA (500/230/190/180) 0 ICD/67 7 m/52 cardiac arrest 0 0 VF CD/64 8 m/30 cardiac arrest SCD 0 ns VT 60 VF RVA (330/200/200) RVA (500/230/210/200) ICD/75 9 m/59 cardiac arrest 0 0 VF 50 nsvt 0 0 Death/3 10 f/66 cardiac arrest 0 0 VF 50 VF RVA (500/230/200/170) 0 ICD/30 11 m/30 cardiac arrest 0 0 VF 40 VF RVO (370/210/170) RVO (370/210/190) ICD/50 12 m/35 cardiac arrest 0 0 VF 55 VF RVA(430/230/180) 0 ICD/9 13 m/48 cardiac arrest SCD VF 60 VF RVA (430/210/190) RVA (430/210/180) ICD/38 14 m/64 syncope syncope + nsvt 70 nsvt 0 0 refused ICD/26 15 m/58 syncope syncope 0 nsvt 60 VF RVO (500/220/180/180) RVO (500/240/210/190) ICD/15 16 m/32 syncope syncope VF RVO (500/220/180/180) 0 ICD/27 17 m/33 syncope VF RVA (500/220/200) 0 ICD/34 18 m/59 syncope 0 0 ns VT 35 VF RVO (330/200/170) 0 ICD/56 19 m/31 syncope VF RVO (370/180/200) RVO (500/210/170/220) refused ICD/27 20 f/43 syncope ns-vt 0 0 ICD/46 21 m/54 syncope VF RVA (500/260/210/160) 0 ICD/44 22 f/59 syncope 0 0 ns VT refused ICD/27 23 f/48 syncope SCD, syncope ICD/40 24 f/52 syncope syncope 0 SVT 45 VF RVO (500/190/170) 0 ICD/28 25 f/28 syncope syncope + SVT 60 VF RVO (300/280/160) RVO (500/230/200/200) ICD/26 26 f/58 syncope syncope refused ICD/23 27 f/57 syncope 0 0 ns VT ICD/50 28 m/55 syncope VT RVO (330/220) 0 ICD/6 29 m/24 syncope syncope VF RVO (500/220/160/170) 0 ICD/7 30 f/22 syncope refused ICD/4 Pt. no.=patient number; Doc.arrhy.=documented arrhythmia; ns VT/VF=non-sustained ventricular tachyarrhythmia/fibrillation; RVO/A=right ventricular outflow tract/apex; =not performed; + =positive; 0=negative; ICD=implantable cardioverter defibrillator (in bold pts with adequate ICD discharge on follow-up), Follow-up in months after ICD implantation.

4 Programmed electrical stimulation in Brugada syndrome 1397 Table 2 Clinical and electrophysiologic characteristics of asymptomatic individuals with an ECG compatible with Brugada syndrome Pt. no. Sex/Age (years) Clinic Family history SCN5A Doc. arrhy. HV (ms) Induction VT/VF Mode of VT/VF induction (ms) Therapy/Follow-up 31 m/50 asymptom VF RVA (370/220/230) RVA (370/200/170) ICD/31 32 m/38 asymptom. SCD no ICD/31 33 m/54 asymptom VF RVA (500/230/170/170) RVA (500/230/170/170) ICD/27 34 m/34 asymptom. syncope no ICD/25 35 m/46 asymptom. SCD VF RVO (500/190/140/150) 0 refused ICD/n.a 36 f/30 asymptom. SCD no ICD/22 37 f/48 asymptom. syncope 0 SVT 40 VF RVA (500/200/170/180) RVO (500/210/180) ICD/29 38 m/57 asymptom. SCD 0 SVT 50 VF RVA (370/210/180) RVA (370/210/160) ICD/16 39 m/61 asymptom. 0 0 ns VT 60 VF RVA (330/210/180) RVA 500/260/220/200 ICD/23 40 m/22 asymptom. syncope VF RVA (500/240/210/220) RVO (500/210/220) ICD/5 41 f/45 asymptom. syncope no ICD/4 Pt. no.=patient number; Doc.arrhy.=documented arrhythmia; ns VT/VF=non-sustained ventricular tachyarrhythmia/fibrillation; RVO/A=right ventricular outflow tract/apex; =not performed; + =positive; 0=negative; ICD=implantable cardioverter defibrillator; n.a.=follow-up data not available.

5 1398 L. Eckardt et al. Table 3 Yield of PVS for stimulation stopped at a coupling interval of 200 ms or continued to refractoriness Coupling interval Symptomatic Asymptomtic 200 msec Refractoriness 200 msec Refractoriness (I) Right ventricular apex n=30 n=11 With 1 premature beat premature beats 3 (10 3%) 5 (17 2%) 1 (9 1%) 3 (27 3%) 3 premature beats 1 (3 4%) 5 (17 2%) 1 (9 1%) 3 (27 3%) N (%) inducible 4 (13 8%) 10 (33 3%) 2 (18 2%) 6 (54 5%) (II) Right ventricular outflow tract n=26* With 1 premature beat 1 (3 4%) 1 (3 4%) premature beats 1 (3 4%) 5 (17 0%) permature beats 2 (6 8%) 5 (17 2%) 0 1 (9 1%) N (%) inducible 4 (13 8%) 11 (37 9%) 0 1 (3 4%) (I)+(II) With 1 premature beat 1 (3 4%) 1 (3 4%) premature beats 4 (13 8%) 10 (34 5%) 1 (9 1%) 3 (27 3%) 3 premature beats 3 (10 33%) 10 (34 5%) 1 (9 1%) 4 (36 4%) N (%) inducible 8 (30 8%) 21 (70 0%) 2 (18 2%) 7 (63 6%) *Only those patients who were not reproducible inducible in the right ventricular apex were stimulated in the ouflow tract. reproducible induction of a sustained ventricular arrhythmia lasting for >30 s, causing syncope, or requiring intervention to be terminated. Reproducibility was tested by repeating stimulation at the same cycle length at which the VT/VF was inducible and by continuation of the protocol. Reproducibility was not tested if the patient refused further stimulation (n=3). Patients with inducible non-sustained ventricular arrhythmias (>6 beats that terminated spontaneously within 30 s) were classified as noninducible. If the endpoint was not reached with two premature beats at one site, three premature beats were administered at a cycle length of 500 ms at the same site. Thereafter, this stimulation protocol was repeated at the right ventricular outflow tract with one, two, and finally three premature beats. Results Programmed ventricular stimulation Sustained ventricular arrhythmias were inducible in the majority of patients (n=28, 68%). Almost all induced arrhythmias were rapid (mean cycle length ms), polymorphic VT that could not be differentiated from VF. A monomorphic VT was inducible in only one patient (patient 5). The highest rate of inducibility occurred in the group of patients who had been resuscitated from cardiac arrest (85%), followed by those who were asymptomatic (64%), and the group of patients with syncopal episodes (59%). Thus, a comparable number of symptomatic (70%) and asymptomatic (64%) individuals were inducible. In those with a positive family history (n=18; 44% of all patients), seven patients (three symptomatic patients) were not inducible. Of all inducible patients (n=28), 16 (57%) patients were already inducible from the right ventricular apex (Table 3). The remaining patients were only inducible from the right ventricular outflow tract. Only one patient (patient 27) was inducible with one extrastimulus. In 17 (61%) of the inducible patients, ventricular arrhythmias were inducible by two premature stimuli whereas in the remaining 11 patients (39%) sustained arrhythmias were only inducible by the third premature stimulus. In 16 of the inducible patients (55%), ventricular arrhythmias were reproducibly inducible. In 29 (66%) of all 44 induced episodes of ventricular arrhythmias, coupling intervals shorter than 200 ms were required to induce sustained arrhythmias. The mean values for two and three premature beats that induced ventricular tachyarrhythmias were ms and ms, respectively. If programmed ventricular stimulation was stopped at a coupling interval of 200 ms, 62% and 71% of the otherwise inducible symptomatic and asymptomatic patients would not have been inducible, respectively, and only 14% would have been inducible twice. In four of the inducible patients, programmed ventricular stimulation was not continued after defibrillation because the patients declined treatment (patients 2, 10, 12) or because of unsterile catheters (patient 6). In the remaining nine inducible patients (32% of all inducible patients; patients 16 18, 21, 24, 28, 29, 35, 40), the inducibility of sustained ventricular arrhythmias was not reproducible. Treatment and clinical follow-up All patients with a history of cardiac arrest, and those with syncope, as well as those with no clinical event, but

6 Programmed electrical stimulation in Brugada syndrome 1399 inducible arrhythmias and/or a family history of sudden cardiac arrest were offered an ICD. The ICD was refused by six patients (patients 14, 19, 22, 26, 30, 35). During a mean follow-up of months (symptomatic patients months vs asymptomatic patients months), four patients (10%) (patients 5, 6, 13, 17) experienced adequate ICD discharges due to spontaneous ventricular arrhythmias. The first episode of VT requiring ICD discharges occurred 4 months (patient 5), 3 months (patient 13), 16 months (patient 6), and 3 months (patient 18) after ICD implantation. All had previously been symptomatic with a history of cardiac arrest (n=3) or syncope (n=1, patient 18) and were inducible during programmed ventricular stimulation (except for patient 9). Patient 5 died suddenly 3 months after ICD implantation. Unfortunately, the ICD was not interrogated. None of the asymptomatic patients became symptomatic (syncope, sustained ventricular arrhythmia) within the mean follow-up of months in this group. Interrogation of the ICD did not reveal non-sustained VT. The shorter follow-up is the result of a later recognition of the asymptomatic individuals during the course of this study. Discussion At present, the role of invasive electrophysiologic testing in patients with Brugada syndrome as well as in asymptomatic individuals with a similar ECG pattern is a matter of some controversy. In contrast to previous studies [2,4,5], the present study is the first to use a uniform stimulation protocol in a large group of individuals with an ECG pattern of atypical right bundle branch block and right precordial ST-segment elevation. The main findings are the following: (1) Of all individuals with an ECG compatible with Brugada syndrome, 68% had inducible sustained VT with the use of three premature beats at five different basic cycle lengths and two ventricular sites. If patients were only stimulated in the right ventricular apex inducibility rate decreased to 39%. If only two premature stimuli at two sites were used it also fell to 32%. (2) The mean coupling intervals of the premature stimuli inducing sustained ventricular arrhythmias were short, with 64% of individuals having inducible sustained tachyarrhythmias with coupling intervals shorter than 200 ms. Thus, 39% of all symptomatic and 45% of the asymptomatic patients would not have been inducible when the stimulation protocol was stopped at a coupling interval of 200 ms. All patients who experienced adequate ICD discharges during follow-up were only inducible with coupling intervals shorter than 200 ms. These data should be considered when programmed ventricular stimulation is used as a diagnostic criterion in patients with right bundle branch block and ST-elevation syndrome. Programmed ventricular stimulation in Brugada syndrome There is general agreement on the overall high rate of inducibility in patients with Brugada syndrome. Most previous studies [7] reported a high degree of inducibility ranging from 30% [8] to 93% [7] and even 100% [9]. Brugada et al. [2] and Priori et al. [5] recently reported multicentre data on 252 (116 symptomatic patients) and 65 patients (31 symptomatic patients) with right bundle branch block and ST-elevation, respectively. Because patients were included at different centres in both studies, the stimulation protocols varied from one centre to another. In the large series reported by Brugada et al. [2], the protocol included a minimum of two basic pacing cycle lengths and a minimum of two premature beats per basic cycle length up to refractoriness or induction of a sustained VT. Priori and coworkers [5] did not further specify the different protocols but a maximum of three premature beats was used. No coupling intervals or data on reproducibility were reported in either study. Brugada et al. [2] reported that 130 of 252 patients (52%) had inducible ventricular arrhythmias whereas Priori et al [5] demonstrated that in 26 (67%) of 39 investigated patients, sustained polymorphic ventricular arrhythmias were inducible (35% with three premature beats). Despite using an identical stimulation protocol with decremental stimulation to the point of refractoriness, nine (30%) out of 30 symptomatic patients (two patients with a history of cardiac arrest, seven with syncope, one with a SCN5A mutation) were not inducible in the present study. In addition, we found that 43% of the inducible patients were only inducible from the right ventricular outflow tract after initial stimulation from the apex had been unremarkable. Thus, the stimulation protocol markedly influences the degree of inducibility in patients with right bundle branch block and ST-elevation in the right precordial leads. Stimulation at other sites i.e. an epicardial site [10] was not investigated in the present study but may increase inducibility. At present, we do not know whether different stimulation protocols will also affect the practical recommendations for patients but our findings question the significance of previous multicentre studies and should have implications for further studies. In the initial study by Brugada and Brugada [1], four of eight patients (two with three extrastimuli) had inducible sustained polymorphic VT degenerating into VF. The initiating ventricular premature beat of the documented VT had a short coupling interval. The present data demonstrated that in the majority of inducible patients, coupling intervals shorter than 200 ms were required to induce sustained ventricular arrhythmias. This observation is in marked contrast to the worldwide experience with programmed ventricular stimulation in patients with structural heart disease. As these patients have an anatomical substrate for arrhythmogenesis, it is more likely to induce sustained arrhythmias with premature stimuli at longer coupling intervals. Thus, although it has previously not been shown, it is not surprising

7 1400 L. Eckardt et al. that short coupling intervals are required in Brugada syndrome patients with normal hearts. Spontaneous VT occurrence in Brugada syndrome The induction of sustained ventricular arrhythmias with short coupling intervals during the remote phase after an arrhythmic event in Brugada syndrome resembles the clinical situation. Viskin et al. [11] reported that spontaneous VF among patients with idiopathic VF has a very distinctive mode of onset. In 32 patients studied, a single premature ventricular complex with a short coupling interval initiated a polymorphic VT, which rapidly deteriorated into VF. Kakishita et al. [9] also demonstrated that premature, short coupled complexes occurred more frequently before the onset of VF in Brugada syndrome. However, the mean coupling interval of the first premature complex of VF reported by Kakishita et al. [9] was 388 ms which is, therefore, much longer than the coupling intervals required during programmed ventricular stimulation. This may indicate the importance of additional environmental factors, a site specificity of the premature ventricular complex and/or the increased vulnerability of the ventricle before spontaneous occurrence of VT as compared to the situation during the electrophysiologic investigation. The aetiology of premature complexes and the mechanism by which they precipitate arrhythmias in patients with Brugada syndrome has not yet been definitely clarified. The short coupled premature beat may meet the heart at a particular vulnerable phase, at a time when there is maximal dispersion of early repolarization. This may create unidirectional block and allow multiple reentrant waves. Antzelevitch et al. [12,13] reported that voltage gradients between sites of action potential dome and those where it is lost may give rise to phase-2- reentry and the generation of a very early ventricular complexes, which is then able to precipitate circus movement reentrant VT. Prognosis and treatment At present, there is much debate on the definition and management strategies in patients with ECG pattern compatible with Brugada syndrome. Brugada et al. [2] reported that the inducibility of ventricular tachyarrhythmias was an excellent predictor of arrhythmia recurrence during a mean follow-up of months. In spite of not having any previous symptoms, about 5% of the individuals with a Brugada typical ECG presented with an arrhythmic event. Only three (one asymptomatic) non-inducible patients became symptomatic during follow-up. However, the asymptomatic patients had only a mean follow-up of 25 months with a large standard deviation of 27 months, and these patients were on average 5 years younger than the symptomatic patients (41 15 years vs years, P<0 007). This may overestimate the negative predictive value of programmed ventricular stimulation in this study. In contrast, Priori et al. [5] found that electrophysiologic testing did not correctly identify patients at high or low risk for cardiac arrest during a comparable follow-up period (positive predictive value 50%, negative predictive value 46%). Because no arrhythmic event was observed in the group of asymptomatic patients it was concluded that in particular these asymptomatic individuals are at very low risk of sudden cardiac death [5]. Our limited experience with a follow-up period of months supports data reported by Priori et al. [5]. We also identified six of 17 (35%) patients with syncope and two of 13 patients (15%) with previous resuscitation who were not inducible. During follow-up, there were only four patients with VF episodes. The majority of all patients (87%) and all asymptomatic patients were free of symptoms during follow-up. However, due to the later recognition of the asymptomatic individuals in the course of this study, which is similar to previous studies [2], the follow-up period of months was shorter as compared to the symptomatic patients and is too short to reassure all asymptomatic patients. The lack of correlation between the inducibility of sustained ventricular arrhythmias during programmed ventricular stimulation and the clinical presentation at diagnosis does not necessarily exclude the possibility that the inducibility may correlate to future arrhythmic events. At present, we recommend ICD in all symptomatic patients for secondary prophylaxis of cardiac arrest irrespective of the results of programmed ventricular stimulation. For those who are asymptomatic, it is always an individualized decision that takes into account multiple parameters, such as sex, family history, ECG pattern (persistent or transient), late potentials [14], body surface potential mapping [15], genetic testing, but also the results of programmed ventricular stimulation. There is, of course, urgent need for practical guidelines but extension of the follow-up period to at least 10 years as suggested by Priori et al. [5] is probably required before drawing definitive conclusions about the risk of death and the prognostic significance of these parameters in patients with Brugada syndrome. References [1] Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: [2] Brugada P, Geelen P, Brugada R, Mont L, Brugada J. Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12: [3] Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105: [4] Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V-1 through V-3: A

8 Programmed electrical stimulation in Brugada syndrome 1401 marker for sudden death in patients without demonstrable structural heart disease structural heart disease. Circulation 1998; 97: [5] Priori SG, Napolitano C, Gasparini M et al. Clinical and genetic heterogeneity of right bundle branch block and ST- Segment elevation syndrome A prospective evaluation of 52 families. Circulation 2000; 102: [6] Eckardt L, Kirchhof P, Loh P et al. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J Cardiovasc Electrophysiol 2001; 12: [7] Nademanee K, Veerakul G, Nimmannit S et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96: [8] Kasanuki H, Ohnishi S, Ohtuka M et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997; 95: [9] Kakishita M, Kurita T, Matsuo K et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000; 36: [10] Carlsson J, Erdogan A, Schulte B, Neuzner J, Pitschner HF. Possible role of epicardial left ventricular programmed stimulation in Brugada syndrome. Pacing Clin Electrophysiol 2001; 24: [11] Viskin S, Lesh MD, Eldar M et al. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1997; 8: [12] Antzelevitch C. The Brugada Syndrome. J Cardiovasc Electrophysiol 1998; 9: [13] Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999; 100: [14] Eckardt L, Bruns H, Kirchhof P et al. Body surface area of ST-elevation and presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. J Cardiovasc Electrophysiol, (in press). [15] Bruns J, Eckardt L, Vahlhaus C et al. Body surface potential mapping in patients with Brugada syndrome: right precordial ST segment variations and reverse changes in left precordial leads. Cardiovasc Res 2002; 54:

Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation

Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation J Arrhythmia Vol 25 No 1 2009 Original Article Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation Seiji Takashio

More information

Are there low risk patients in Brugada syndrome?

Are there low risk patients in Brugada syndrome? Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the

More information

The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol

The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol European Heart Journal (2003) 24, 1104 1112 The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol Sascha Rolf*, Hans-Jürgen Bruns, Thomas Wichter, Paulus Kirchhof,

More information

P. Brugada 1, R. Brugada 2 and J. Brugada 3. Introduction. U.S.A.; 3 Unitat d Arritmias, Hospital Clinic, Barcelona, Spain

P. Brugada 1, R. Brugada 2 and J. Brugada 3. Introduction. U.S.A.; 3 Unitat d Arritmias, Hospital Clinic, Barcelona, Spain European Heart Journal (2000) 21, 321 326 Article No. euhj.1999.1751, available online at http://www.idealibrary.com on Sudden death in patients and relatives with the syndrome of right bundle branch block,

More information

Brugada syndrome is a cardiac disease caused by an

Brugada syndrome is a cardiac disease caused by an Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome Bernard Belhassen, MD; Aharon Glick, MD; Sami Viskin, MD Background Automatic implantable cardioverter-defibrillator therapy is considered

More information

CME Article Brugada pattern masking anterior myocardial infarction

CME Article Brugada pattern masking anterior myocardial infarction Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University

More information

Risk Stratification for Asymptomatic Patients With Brugada Syndrome

Risk Stratification for Asymptomatic Patients With Brugada Syndrome Circ J 2003; 67: 312 316 Risk Stratification for Asymptomatic Patients With Brugada Syndrome Prediction of Induction of Ventricular Fibrillation by Noninvasive Methods Hiroshi Morita, MD; Shiho Takenaka-Morita,

More information

Tailored treatment in Brugada syndrome

Tailored treatment in Brugada syndrome Tailored treatment in Brugada syndrome Lars Eckardt Department of Cardiology and Angiology Division of Experimental and Clinical Electrophysiology University of Münster, Germany 45 yr old male preoperative

More information

The Electrophysiologic Mechanism of ST-Segment Elevation in Brugada Syndrome

The Electrophysiologic Mechanism of ST-Segment Elevation in Brugada Syndrome Journal of the American College of Cardiology Vol. 40, No. 2, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01964-2

More information

The Brugada Syndrome: An Easily Identified and Preventable Cause of Sudden Cardiac Death

The Brugada Syndrome: An Easily Identified and Preventable Cause of Sudden Cardiac Death The Brugada Syndrome: An Easily Identified and Preventable Cause of Sudden Cardiac Death Raymond Farah, MD 1, Elias Nassir, MD 2, Rola Farah, MD 3, Moshe Shai, MD 4 Nathan Roguin, MD 5 1 Department of

More information

Optimal management of Brugada syndrome

Optimal management of Brugada syndrome Optimal management of Brugada syndrome Cristian Stătescu 1,2, Teodor Vasilcu 1,2, Ioana Mădălina Chiorescu*,1,2, Grigore Tinică 1,2, Cătălina Arsenescu-Georgescu 1,2, Radu Sascău 1,2 1 "Grigore T. Popa"

More information

The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia

The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology

More information

Case Presentation. Asaad Khan University College Hospital Galway Rep of Ireland

Case Presentation. Asaad Khan University College Hospital Galway Rep of Ireland Case Presentation Asaad Khan University College Hospital Galway Rep of Ireland Case History 32 male Married Working as a chartered accountant P/C:Admitted to a Regional hospital to be investigated for

More information

J Wave Syndromes. Osama Diab Lecturer of Cardiology Ain Shams University

J Wave Syndromes. Osama Diab Lecturer of Cardiology Ain Shams University J Wave Syndromes Osama Diab Lecturer of Cardiology Ain Shams University J Wave Syndromes Group of electric disorders characterized by > 1 mm elevation of the J point or prominent J wave with or without

More information

Approximately 5% of patients who experience sudden death

Approximately 5% of patients who experience sudden death Sodium Channel Blockers Identify Risk for Sudden Death in Patients With ST-Segment Elevation and Right Bundle Branch Block but Structurally Normal Hearts Ramon Brugada, MD; Josep Brugada, MD; Charles Antzelevitch,

More information

Silvia G Priori MD PhD

Silvia G Priori MD PhD The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics

More information

ICD in a young patient with syncope

ICD in a young patient with syncope ICD in a young patient with syncope Konstantinos P. Letsas, MD, FESC Second Department of Cardiology Evangelismos General Hospital of Athens Athens, Greece Case presentation A 17-year-old apparently healthy

More information

State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification

State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification Lars Eckardt Division Electrophysiology Department of Cardiovascular Medicine University of Münster, Germany I have

More information

Name of Presenter: Marwan Refaat, MD

Name of Presenter: Marwan Refaat, MD NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have no actual or potential conflict of interest in relation

More information

Journal of the American College of Cardiology Vol. 40, No. 2, by the American College of Cardiology Foundation ISSN /02/$22.

Journal of the American College of Cardiology Vol. 40, No. 2, by the American College of Cardiology Foundation ISSN /02/$22. Journal of the American College of Cardiology Vol. 40, No. 2, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01962-9

More information

When VF is the endpoint, wait and see is not always the best option.

When VF is the endpoint, wait and see is not always the best option. Being free of symptoms does not necessarily mean free of arrhythmias. This Holter is from a asymptomatic 48 years old female with LQT2 When VF is the endpoint, wait and see is not always the best option.

More information

Supraventricular arrhythmias in Brugada syndrome. Prof. Dr. Martin Borggrefe Mannheim

Supraventricular arrhythmias in Brugada syndrome. Prof. Dr. Martin Borggrefe Mannheim Supraventricular arrhythmias in Brugada syndrome Prof. Dr. Martin Borggrefe Mannheim Brugada syndrome 1992-2012 Time interval between description of the disease and discovery of first causal gene Brugada

More information

Atrial Fibrillation and Brugada Syndrome

Atrial Fibrillation and Brugada Syndrome Journal of the American College of Cardiology Vol. 51, No. 12, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.062

More information

Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?

Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC

More information

Tachycardias II. Štěpán Havránek

Tachycardias II. Štěpán Havránek Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia

More information

Ripolarizzazione precoce. Torino, 24th October Non così innocente come si pensava

Ripolarizzazione precoce. Torino, 24th October Non così innocente come si pensava Asymptomatic inherited arrhythmia syndromes: Drug induced Brugada Syndrome: when a prophylactic ICD is indicated? how high (or low) is QT the risk? Asymptomatic short Ripolarizzazione precoce. Torino,

More information

Ventricular Arrhythmia Induced by Sodium Channel Blocker in Patients With Brugada Syndrome

Ventricular Arrhythmia Induced by Sodium Channel Blocker in Patients With Brugada Syndrome Journal of the American College of Cardiology Vol. 42, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)01124-0

More information

Brugada Syndrome: Age is just a number

Brugada Syndrome: Age is just a number Brugada Syndrome: Age is just a number 1 Deepthi Kagolanu, MD, 2 Cynthia Pacas, 1 Usman Jilani, DO, 1 Ebisa Bekele, MD, 3 Christopher Henessey, 4 Kent Stephenson MD 1 Nassau University Medical Center,

More information

Ventricular fibrillation is the main mechanism involved in

Ventricular fibrillation is the main mechanism involved in Short QT Syndrome A Familial Cause of Sudden Death Fiorenzo Gaita, MD; Carla Giustetto, MD; Francesca Bianchi, MD; Christian Wolpert, MD; Rainer Schimpf, MD; Riccardo Riccardi, MD; Stefano Grossi, MD;

More information

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας και Βηματοδότησης BrS: Diagnosis 5:10000 First described

More information

Clinical profile and genetic basis of Brugada syndrome in the Chinese population

Clinical profile and genetic basis of Brugada syndrome in the Chinese population ORIGINAL ARTICLE CME NS Mok SG Priori C Napolitano KK Chan R Bloise HW Chan WH Fung YS Chan WK Chan C Lam NY Chan HH Tsang Key words: Arrhythmia; Chinese; Death, sudden, cardiac; Genetics; Recurrence!!"!"#

More information

Chapter 16: Arrhythmias and Conduction Disturbances

Chapter 16: Arrhythmias and Conduction Disturbances Complete the following. Chapter 16: Arrhythmias and Conduction Disturbances 1. Cardiac arrhythmias result from abnormal impulse, abnormal impulse, or both mechanisms together. 2. is the ability of certain

More information

Low Prevalence of Risk Markers in Cases of Sudden Death Due to Brugada Syndrome

Low Prevalence of Risk Markers in Cases of Sudden Death Due to Brugada Syndrome Journal of the American College of Cardiology Vol. 57, No. 23, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.067

More information

Prevention of Sudden Death in ARVC

Prevention of Sudden Death in ARVC ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück

More information

Index. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A AEDs. See Automated external defibrillators (AEDs) AF. See Atrial fibrillation (AF) Age as factor in SD in marathon runners, 45 Antiarrhythmic

More information

Ventricular tachycardia Ventricular fibrillation and ICD

Ventricular tachycardia Ventricular fibrillation and ICD EKG Conference Ventricular tachycardia Ventricular fibrillation and ICD Samsung Medical Center CCU D.I. Hur Ji Won 2006.05.20 Ventricular tachyarrhythmia ventricular tachycardia ventricular fibrillation

More information

A case of Brugada syndrome coexisting with vasospastic angina: Caution should be taken when using calcium channel blockers

A case of Brugada syndrome coexisting with vasospastic angina: Caution should be taken when using calcium channel blockers Journal of Cardiology Cases (2011) 4, e143 e147 Available online at www.sciencedirect.com jou rn al h om epa g e: www.elsevier.com/locate/jccase Case Report A case of Brugada syndrome coexisting with vasospastic

More information

Ablative Therapy for Ventricular Tachycardia

Ablative Therapy for Ventricular Tachycardia Ablative Therapy for Ventricular Tachycardia Nitish Badhwar, MD, FACC, FHRS 2 nd Annual UC Davis Heart and Vascular Center Cardiovascular Nurse / Technologist Symposium May 5, 2012 Disclosures Research

More information

2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC

2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC 2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential

More information

Brugada Syndrome: An Update

Brugada Syndrome: An Update Brugada Syndrome: An Update Osama Diab Associate professor of Cardiology Ain Shams university, Cairo, Egypt Updates Mechanism and Genetics Risk stratification Treatment 1 Brugada syndrome causes 4 12%

More information

Quinidine for Brugada syndrome: Panacea or poison?

Quinidine for Brugada syndrome: Panacea or poison? Quinidine for Brugada syndrome: Panacea or poison? Jo-Jo Hai, MBBS, * Chun-Ka Wong, MBBS, * Pak-Hei Chan, MBBS, * Hung-Fat Tse, MD, PhD, * Tak-Cheung Yung, MBBS, Chung-Wah Siu, MD From the * Division of

More information

Journal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.

Journal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20. Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary

More information

Basic Electrophysiology Protocols

Basic Electrophysiology Protocols Indian Journal of Cardiology ISSN-0972-1622 2012 by the Indian Society of Cardiology Vol. 15, (3-4), 27-37 [ 27 Review Article Shomu Bohora Assistant Professor, Deptt. of Cardiology, U.N. Mehta Institute

More information

Type 1 electrocardiographic burden is increased in symptomatic patients with Brugada syndrome

Type 1 electrocardiographic burden is increased in symptomatic patients with Brugada syndrome Available online at www.sciencedirect.com Journal of Electrocardiology 43 (2010) 408 414 www.jecgonline.com Type 1 electrocardiographic burden is increased in symptomatic patients with Brugada syndrome

More information

Ventricular arrhythmias in acute coronary syndromes. Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital

Ventricular arrhythmias in acute coronary syndromes. Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital Ventricular arrhythmias in acute coronary syndromes Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital introduction myocardial ischaemia and infarction leads to severe

More information

Stefan Peters* Introduction. Methods. * Corresponding author. Tel: þ address:

Stefan Peters* Introduction. Methods. * Corresponding author. Tel: þ address: Europace (2008) 10, 816 820 doi:10.1093/europace/eun030 Arrhythmogenic right ventricular dysplasia-cardiomyopathy and provocable coved-type ST-segment elevation in right precordial leads: clues from long-term

More information

Appearance of J wave in the inferolateral leads and ventricular fibrillation provoked by mild hypothermia in a patient with Brugada syndrome

Appearance of J wave in the inferolateral leads and ventricular fibrillation provoked by mild hypothermia in a patient with Brugada syndrome Appearance of J wave in the inferolateral leads and ventricular fibrillation provoked by mild hypothermia in a patient with Brugada syndrome Yasuaki Hada, MD, * Mitsuhiro Nishizaki, MD, * Noriyoshi Yamawake,

More information

A case of convulsion: Brugada syndrome

A case of convulsion: Brugada syndrome Hong Kong Journal of Emergency Medicine A case of convulsion: Brugada syndrome CK Shum, ML Tse, FL Lau, WK Chan A healthy 28-year-old man presented with multiple brief episodes of convulsion. He was found

More information

INTRODUCTION. left ventricular non-compaction is a sporadic or familial cardiomyopathy characterized by

INTRODUCTION. left ventricular non-compaction is a sporadic or familial cardiomyopathy characterized by A Rare Case of Arrhythmogenic Right Ventricular Cardiomyopathy Co-existing with Isolated Left Ventricular Non-compaction NS Yelgeç, AT Alper, Aİ Tekkeşin, C Türkkan INTRODUCTION Arrhythmogenic right ventricular

More information

Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013

Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013 Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: WPW Revised: 11/2013 Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the

More information

The patient with (without) an ICD and heart failure: Management of electrical storm

The patient with (without) an ICD and heart failure: Management of electrical storm ISHNE Heart Failure Virtual Symposium April 2008 The patient with (without) an ICD and heart failure: Management of electrical storm Westfälische Wilhelms-Universität Münster Günter Breithardt, MD, FESC,

More information

Atrial Fibrillation and Atrial Vulnerability in Patients With Brugada Syndrome

Atrial Fibrillation and Atrial Vulnerability in Patients With Brugada Syndrome Journal of the American College of Cardiology Vol. 40, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02167-8

More information

Clinical Cardiac Electrophysiology

Clinical Cardiac Electrophysiology Clinical Cardiac Electrophysiology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of

More information

Death after Syncope: Can we predict it? Daniel Zamarripa, MD Senior Medical Director December 2013

Death after Syncope: Can we predict it? Daniel Zamarripa, MD Senior Medical Director December 2013 Death after Syncope: Can we predict it? Daniel Zamarripa, MD Senior Medical Director December 2013 Death after Syncope: Can we predict it? Those who suffer from frequent and severe fainting often die suddenly

More information

Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm

Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:

More information

Case Report. Faculty of Medicine, Oita University 2 Department of Cardiology, Hakuaikai Hospital

Case Report. Faculty of Medicine, Oita University 2 Department of Cardiology, Hakuaikai Hospital Case Report Manifestation of ST-Segment Elevation in Right Precordial Leads during schemia at a Right Ventricular Outflow Tract rea in a Patient with rugada Syndrome Naohiko Takahashi MD 1, Tetsuji Shinohara

More information

Ventricular arrhythmias

Ventricular arrhythmias Ventricular arrhythmias Assoc.Prof. Lucie Riedlbauchová, MD, PhD Department of Cardiology University HospitalMotol and2nd FacultyofMedicine, Charles University in Prague Definition and classification Ventricular

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the

More information

Asymptomatic patient with WPW

Asymptomatic patient with WPW Asymptomatic patient with WPW Dimosthenis Avramidis, MD. Arrythmiologist Mitera Children s Hospital Athens Greece Scientific Associate 1st Cardiology Dpt Evangelismos Hospital Athens Greece Preexcitation

More information

Treatment of VT of Purkinje fiber origin: ablation targets and outcome

Treatment of VT of Purkinje fiber origin: ablation targets and outcome Treatment of VT of Purkinje fiber origin: ablation targets and outcome Ch. Piorkowski University Leipzig - Heart Center - Dept. of Electrophysiology Leipzig, Germany Presenter Disclosure Information Gerhard

More information

Proposed Diagnostic Criteria for the Brugada Syndrome

Proposed Diagnostic Criteria for the Brugada Syndrome European Heart Journal (2002) 23, 1648 1654 doi:10.1053/euhj.2002.3382, available online at http://www.idealibrary.com on Consensus Report Proposed Diagnostic Criteria for the Brugada Syndrome A. A. M.

More information

Advances in Ablation Therapy for Ventricular Tachycardia

Advances in Ablation Therapy for Ventricular Tachycardia Advances in Ablation Therapy for Ventricular Tachycardia Nitish Badhwar, MD, FACC, FHRS Director, Cardiac Electrophysiology Training Program University of California, San Francisco For those of you who

More information

Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators

Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators 22 March 2002 Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators F. HINTRINGER, O. PACHINGER Division of Cardiology, Department for Internal Medicine, University

More information

J-wave syndromes: update on ventricular fibrillation mechanisms

J-wave syndromes: update on ventricular fibrillation mechanisms J-wave syndromes: update on ventricular fibrillation mechanisms Michael Nabauer University of Munich, Germany 28.8.2011 I have no conflicts of interest ECG labelling by Einthoven Circ 1998 Osborn wave

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review

More information

Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks

Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated

More information

The patient with electric storm

The patient with electric storm The complex patient in the cardiac care unit: The patient with electric storm Helmut U. Klein University of Rochester Medical Center Heart Research Follow-up Program and Isar Heart Center Muenchen Presenter

More information

Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis

Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Investigator: Keiko Saito, MD Mentor: Yuji Saito, MD, PhD, FACP, FACC Department

More information

Vagally mediated ventricular arrhythmia in Brugada syndrome

Vagally mediated ventricular arrhythmia in Brugada syndrome Vagally mediated ventricular arrhythmia in Brugada syndrome Nicholay Teodorovich, MD, FHRS, * Yonatan Kogan, MD, * Offir Paz, MD, * Moshe Swissa, MD, FHRS * From the * Department of Cardiology, Kaplan

More information

Arrhythmias Focused Review. Who Needs An ICD?

Arrhythmias Focused Review. Who Needs An ICD? Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes

More information

Unusual Tachycardia Association In A patient Without Structural Heart Disease

Unusual Tachycardia Association In A patient Without Structural Heart Disease www.ipej.org 233 Case Report Unusual Tachycardia Association In A patient Without Structural Heart Disease Eduardo Arana-Rueda, Alonso Pedrote, Lorena Garcia-Riesco, Manuel Frutos-Lopez, Juan A. Sanchez-Brotons

More information

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology

More information

ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON

ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON EUROPACE 2011 INHERITED ELECTRICAL CARDIAC DISORDERS ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON June 26 th 2011 Robert Lemery MD CONFLICTS of INTEREST None ASYMPTOMATIC ARVC 1. ECG 2. ASYMPTOMATIC PVC

More information

Case Report Accelerated Idioventricular Rhythm During Ajmaline Test: a Case Report

Case Report Accelerated Idioventricular Rhythm During Ajmaline Test: a Case Report www.ipej.org 474 Case Report Accelerated Idioventricular Rhythm During Ajmaline Test: a Case Report Antonio Sorgente, MD 1,2, Yoshinao Yazaki, MD 1, Lucio Capulzini, MD 1, Andrea Sarkozy, MD 1, Carlo de

More information

Case Demonstrations in Congenital and Acquired Long QT Syndrome

Case Demonstrations in Congenital and Acquired Long QT Syndrome Case Demonstrations in Congenital and Acquired Long QT Syndrome Can You Make A Correct ECG Interpretation? Li Zhang, MD; 1-2 G. Michael Vincent, MD 1 1. LQTS Studies, Department t of Medicine i LDS Hospital,

More information

Case Report Simultaneous Accessory Pathway and AV Node Mechanical Block

Case Report Simultaneous Accessory Pathway and AV Node Mechanical Block 185 Case Report Simultaneous Accessory Pathway and AV Node Mechanical Block Daniel Garofalo, MD, FRACP, Alfonso Gomez Gallanti, MD, David Filgueiras Rama, MD, Rafael Peinado Peinado, PhD, FESC Unidad de

More information

M Furuhashi, K Uno, K Tsuchihashi, D Nagahara, M Hyakukoku, T Ohtomo, S Satoh, T Nishimiya, K Shimamoto

M Furuhashi, K Uno, K Tsuchihashi, D Nagahara, M Hyakukoku, T Ohtomo, S Satoh, T Nishimiya, K Shimamoto Heart 2001;86:161 166 161 Second Department of Internal Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo 060-0061, Japan M Furuhashi K Uno K Tsuchihashi D Nagahara M

More information

Introduction Implantation of an automatic cardioverterdefibrillator

Introduction Implantation of an automatic cardioverterdefibrillator Excellent Long-Term Reproducibility of the Electrophysiologic Efficacy of Quinidine in Patients with Idiopathic Ventricular Fibrillation and Brugada Syndrome BERNARD BELHASSEN, M.D., AHARON GLICK, M.D.,

More information

Urgent VT Ablation in a Patient with Presumed ARVC

Urgent VT Ablation in a Patient with Presumed ARVC Urgent VT Ablation in a Patient with Presumed ARVC Mr Alex Cambridge, Chief Cardiac Physiologist, St. Barts Hospital, London, UK The patient, a 52 year-old male, attended the ICD clinic without an appointment

More information

When the rhythm of life is disturbed

When the rhythm of life is disturbed Brugada Syndrome has the capacity to cause abnormal heart rhythms originating in the upper chambers of the heart When the rhythm of life is disturbed Cardiovascular disease continues to be a leading cause

More information

Defibrillator Versus -Blockers for Unexplained Death in Thailand (DEBUT) A Randomized Clinical Trial

Defibrillator Versus -Blockers for Unexplained Death in Thailand (DEBUT) A Randomized Clinical Trial Defibrillator Versus -Blockers for Unexplained Death in Thailand (DEBUT) A Randomized Clinical Trial Koonlawee Nademanee, MD; Gumpanart Veerakul, MD; Morton Mower, MD; Khanchit Likittanasombat, MD; Rungroj

More information

Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome

Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome Europace (2016) 18, 1501 1506 doi:10.1093/europace/euw008 REVIEW Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome Bieke Dobbels 1 *, Dieter De Cleen 2,3, and Joris Ector 4,5 1

More information

FANS Paediatric Pathway for Inherited Arrhythmias*

FANS Paediatric Pathway for Inherited Arrhythmias* FANS Paediatric Pathway for Inherited Arrhythmias* The pathway is based on the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes

More information

Ventricular Arrhythmias

Ventricular Arrhythmias Presenting your most challenging cases Venice Arrhythmias Ventricular Arrhythmias Gioia Turitto, MD Presenter Disclosure Information A questionable indication for CRT-D in a patient with VT after successful

More information

Benign RVOT Ectopy and RV dysplasia

Benign RVOT Ectopy and RV dysplasia Heart Rhythm Congress Birmingham October 2009 How to distinguish between... Benign RVOT Ectopy and RV dysplasia in the child... Dr Graham Stuart 14yr old boy asymptomatic irregular pulse picked up by GP

More information

Augmented ST-Segment Elevation During Recovery From Exercise Predicts Cardiac Events in Patients With Brugada Syndrome

Augmented ST-Segment Elevation During Recovery From Exercise Predicts Cardiac Events in Patients With Brugada Syndrome Journal of the American College of Cardiology Vol. 56, No. 19, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.201.033 Heart

More information

Short QT Syndrome: Pharmacological Treatment

Short QT Syndrome: Pharmacological Treatment Journal of the American College of Cardiology Vol. 43, No. 8, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.02.034

More information

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes RHEA C. PIMENTEL, MD, FACC, FHRS UNIVERSITY OF KANSAS HOSPITAL MID AMERICA CARDIOLOGY AUGUST 19, 2012 Monogenic Arrhythmia Syndromes Mendelian

More information

Congenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene

Congenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene CASE REPORT Cardiology Journal 2013, Vol. 20, No. 1, pp. 78 82 10.5603/CJ.2013.0012 Copyright 2013 Via Medica ISSN 1897 5593 Congenital long QT syndrome of particularly malignant course connected with

More information

How to manage a patient with short QT syndrome?

How to manage a patient with short QT syndrome? How to manage a patient with short QT syndrome? Torino, 27 ottobre2012 Carla Giustetto Division of Cardiology University of Torino QT 280 ms QTc 260 ms Narrow, tall and peaked T waves High incidence of

More information

How agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona

How agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona How agressively should we treat asymptomatic patients with Brugada syndrome Josep Brugada Medical Director Hospital Clínic, University of Barcelona The ECG in Brugada syndrome - Prolonged PR - RBBB - ST

More information

Invasive Risk Stratification: When is it needed?

Invasive Risk Stratification: When is it needed? Inherited Cardiomyopathies and Channelopathies: Who is at risk for Sudden Cardiac Death? Invasive Risk Stratification: When is it needed? Hung-Fat Tse, MD, PhD Department of Medicine The University of

More information

Heart Rhythm Disorders. How do you quantify risk?

Heart Rhythm Disorders. How do you quantify risk? Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.

More information

In 1992, Brugada and Brugada 1 reported 8 patients resuscitated

In 1992, Brugada and Brugada 1 reported 8 patients resuscitated Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome A Prospective Evaluation of 52 Families Silvia G. Priori, MD, PhD; Carlo Napolitano, MD, PhD; Maurizio

More information

CLINICAL CARDIAC ELECTROPHYSIOLOGY Maintenance of Certification (MOC) Examination Blueprint

CLINICAL CARDIAC ELECTROPHYSIOLOGY Maintenance of Certification (MOC) Examination Blueprint CLINICAL CARDIAC ELECTROPHYSIOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Clinical Cardiac Electrophysiology MOC exam blueprint Based on feedback

More information

13/09/2018. The ISSUE Studies. International (Italy & Spain) Study of Syncope of Uncertain Etiology. ISSUE study Pre-defined inclusion cathegories

13/09/2018. The ISSUE Studies. International (Italy & Spain) Study of Syncope of Uncertain Etiology. ISSUE study Pre-defined inclusion cathegories The Studies Jean-Claude Deharo Aix-Marseille Université, France In Cardiac Electrophysiology Methods and Models Editors: Daniel C. Sigg, Paul A. Iaizzo, Yong-Fu Xiao, Bin He Springer 2010 study Pre-defined

More information

ECG Workshop. Carolyn Shepherd And Anya Horne UWE Principles of Cardiac Care

ECG Workshop. Carolyn Shepherd And Anya Horne UWE Principles of Cardiac Care ECG Workshop Carolyn Shepherd And Anya Horne UWE Principles of Cardiac Care ECG workshop case study1 44 Year old male. Reports SOB, Lethargy, tiredness. PMH: Hypertension, nil else. What tests? What treatment?

More information

Ventricular fibrillation and sudden death may occur in

Ventricular fibrillation and sudden death may occur in Right Bundle Branch Block, Right Precordial ST-Segment Elevation, and Sudden Death in Young People Domenico Corrado, MD; Cristina Basso, MD, PhD; Gianfranco Buja, MD; Andrea Nava, MD; Lino Rossi, MD; Gaetano

More information

EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs

EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for

More information

«Aσθενής με ασυμπτωματικό WPW και παροξυσμική κολπική μαρμαρυγή» Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.

«Aσθενής με ασυμπτωματικό WPW και παροξυσμική κολπική μαρμαρυγή» Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. «Aσθενής με ασυμπτωματικό WPW και παροξυσμική κολπική μαρμαρυγή» Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» the primary mechanism of SCD in patients with WPW is the rapid conduction

More information